FDA approves Johnson & Johnson’s nasal spray for depression

FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
FDA Approves Nasal Spray for Depression
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants.
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
New Nasal Spray to Treat Depression Gets FDA Approval
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression. Johnson & Johnson said patients who use the nasal spray Spravato—which is made from the drug esketamine—may see improvements in depressive symptoms in as little as 24 hours.
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with major depressive disorder, the company said on Tuesday. The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants.
FDA allows standalone use of nasal spray antidepressant Spravato
The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
Blue Monday isn’t real, but seasonal depression affects millions of people. There are ways to treat it
Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...
What's the Connection Between Weight & Depression?
Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...
mic3h
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Inauguration Day in photos, the allure of coffee shops, how to handle seasonal depression: Catch up on the day’s stories
Inauguration Day in photos, the allure of coffee shops, how to handle seasonal depression: Catch up on the day’s stories ...
Science Daily1d
Depression News
Jan. 14, 2025 — Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term use of conventional antidepressants, there is a need ...
Drawing a line from the gut microbiome to inflammation and depression
It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial ...
France has the highest levels of depression in Europe. How does it compare with other countries?
A new report studied depression levels across Europe and in older and younger individuals, with the outlook for France ...
L.A.’s Record-Breaking 262-Day Dry Spell Is Finally Ending
The historic dry spell that fueled the devastating Los Angeles wildfires is expected to end this weekend. Forecasters expect light rain and mountain snow on Saturday, ending 262 days and counting ...